Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER

Abstract Introduction The HAWK and HARRIER studies evaluated the efficacy and safety of brolucizumab versus aflibercept in treatment-naïve eyes with neovascular age-related macular degeneration. Based on the study design, brolucizumab-treated eyes adjusted to a q8w regimen because the presence of di...

Full description

Bibliographic Details
Main Authors: Ramin Tadayoni, Glenn J. Jaffe, Frank G. Holz, Ursula Schmidt-Erfurth, Kanji Takahashi, Chui Ming Gemmy Cheung, Seenu M. Hariprasad, Kinfemichael Gedif, Rasmus Olsen, Catherine Best, Franklin Igwe, Peter K. Kaiser
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-06-01
Series:Ophthalmology and Therapy
Subjects:
Anti-VEGF therapy
Brolucizumab
Disease activity
Interval extension
Neovascular age-related macular degeneration
Online Access:https://doi.org/10.1007/s40123-023-00735-8

Internet

https://doi.org/10.1007/s40123-023-00735-8

Similar Items